全文获取类型
收费全文 | 15099篇 |
免费 | 1236篇 |
国内免费 | 37篇 |
学科分类
医药卫生 | 16372篇 |
出版年
2023年 | 84篇 |
2021年 | 245篇 |
2020年 | 198篇 |
2019年 | 227篇 |
2018年 | 296篇 |
2017年 | 231篇 |
2016年 | 241篇 |
2015年 | 239篇 |
2014年 | 387篇 |
2013年 | 665篇 |
2012年 | 866篇 |
2011年 | 942篇 |
2010年 | 550篇 |
2009年 | 543篇 |
2008年 | 948篇 |
2007年 | 984篇 |
2006年 | 1029篇 |
2005年 | 980篇 |
2004年 | 962篇 |
2003年 | 967篇 |
2002年 | 952篇 |
2001年 | 166篇 |
2000年 | 101篇 |
1999年 | 134篇 |
1998年 | 179篇 |
1997年 | 162篇 |
1996年 | 160篇 |
1995年 | 160篇 |
1994年 | 137篇 |
1993年 | 106篇 |
1992年 | 109篇 |
1991年 | 107篇 |
1990年 | 101篇 |
1989年 | 78篇 |
1988年 | 92篇 |
1987年 | 79篇 |
1986年 | 94篇 |
1985年 | 95篇 |
1984年 | 123篇 |
1983年 | 129篇 |
1982年 | 155篇 |
1981年 | 136篇 |
1980年 | 152篇 |
1979年 | 72篇 |
1978年 | 111篇 |
1977年 | 90篇 |
1976年 | 94篇 |
1974年 | 67篇 |
1973年 | 56篇 |
1972年 | 62篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Keith B. Diamond Ivan J. Golub Asad M. Ashraf Samuel J. Swiggett Paul V. Romeo Jack Choueka 《Seminars in Arthroplasty》2022,32(1):15-22
BackgroundWhile studies have demonstrated favorable outcomes in utilization of primary total shoulder arthroplasty (TSA) for the treatment of glenohumeral osteoarthritis (OA), adverse events such as infections can still occur. Periprosthetic joint infections (PJIs) are associated with worse outcomes and patient morbidity. The purpose of this study was to: (1) compare patient demographics amongst TSA patients with and without PJIs following primary TSA; and (2) identify patient-related risk factors for PJIs following primary TSA.MethodsPatients undergoing primary TSA for the treatment of glenohumeral OA were identified using the Mariner administrative claims database by CPT code 23,472. Laterality modifiers were utilized to ensure PJIs were developing in the correct laterality as those patients undergoing primary TSA. Inclusion for the study group consisted of patients who developed PJIs within 2-years after the index procedure, whereas patients who did not develop PJIs served as the comparison cohort. Primary outcomes analyzed included patient demographics and patient-related risk factors for PJIs following primary TSA. A stepwise backwards elimination multivariate binomial logistic regression analyses was performed to determine the odds (OR) of PJIs in patients undergoing primary TSA. A P value less than .05 was considered statistically significant.ResultsThe query yielded 15,396 patients who underwent primary TSA for glenohumeral OA, of which 191 patients developed PJIs and 15,205 did not develop PJIs. The study found statistically significant differences amongst patients who did and did not develop PJIs following primary TSA with respect to age, sex, and presence of comorbid conditions. Risk factors associated with developing PJIs following primary TSA included: pathologic weight loss (OR: 2.06, P < .0001), obesity (OR: 1.56, P = .0001), male sex (OR: 1.52, P = .007), and peripheral vascular disease (OR: 1.46, P = .022).ConclusionAs the number of primary TSAs for the treatment of glenohumeral OA increase worldwide, identifying modifiable risk-factors to reduce the incidence of infection is critical. The study found various modifiable and non-modifiable risk factors associated with developing PJIs following primary TSA. This study is valuable to orthopedists in order to identify and risk-stratify patients with regard to PJI in the setting of primary TSA for OA.Level of EvidenceLevel III; Case-Control Study 相似文献
2.
3.
4.
Andreas Glenthj Lasse H. Jakobsen Henrik Sengelv Syed A. Ahmad Kristian Qvist Annika Rewes Christian B. Poulsen Ulrik M. Overgaard Ingolf Mlle Marianne T. Severinsen Casper N. Strandholdt Jack Maibom Annette R. Kodahl Jesper Ryg Pernille Ravn Isik S. Johansen Sren N. Hels Sren Jensen‐Fangel Jacek Kisielewicz Lothar Wiese Marie Helleberg Ole Kirk Michael R. Clausen Henrik Frederiksen 《European journal of haematology》2021,106(1):72-81
5.
6.
7.
8.
9.
Mandar Jog Jack Lee Astrid Scheschonka Robert Chen Farooq Ismail Chris Boulias Douglas Hobson David King Michael Althaus Olivier Simon Hanna Dersch Steven Frucht David M. Simpson 《Toxins》2020,12(12)
In this first, double-blind, randomized, placebo-controlled exploratory trial, we evaluate the efficacy and safety of incobotulinumtoxinA and feasibility of using kinematic tremor assessment to aid in the planning of muscle selection in a multicenter setting. Reproducibility of the planning technology to other clinical sites was explored. In this trial (), patients with upper-limb essential tremor (ET) were randomized 2:1 to a single treatment cycle of incobotulinumtoxinA or placebo. A tremor kinematic analytics investigational device was used to define a customized muscle set for injection, related to the pattern of the wrist, forearm, elbow, and shoulder tremor for each patient, and the incobotulinumtoxinA dose per muscle (total ≤ 200 U). Fahn–Tolosa–Marin (FTM) Part B motor performance score, Global Impression of Change Scale (GICS), and kinematic analysis-based efficacy evaluations were assessed. Thirty patients were randomized (incobotulinumtoxinA, n = 19; placebo, n = 11). FTM motor performance scores showed greater improvement with incobotulinumtoxinA versus placebo at Week 4 (p = 0.003) and Week 8 (p = 0.031). The physician-rated GICS score indicated improvement with incobotulinumtoxinA versus placebo at Week 4 (p < 0.05). IncobotulinumtoxinA also decreased accelerometric hand-tremor amplitude versus placebo from baseline to Week 4 (p = 0.004) and Week 8 (p < 0.001), with persistent tremor reduction up to 24 weeks post-injection. IncobotulinumtoxinA produced a slight and transient reduction of maximal grip strength versus placebo; two patients reported localized finger muscle weakness. Customized incobotulinumtoxinA injections decreased tremor severity and improved hand motor function in patients with upper-limb ET after a single injection cycle, with a favorable tolerability profile. The study showed that tremor kinematic analytics technology could be successfully scaled for use in other clinical sites. NCT02207946相似文献